TREM2 Antibody [Alexa Fluor® 532]

• Reactivity: Mu
• Applications: WB, ELISA, ICC/IF, KO
• Clonality: Polyclonal
• Host: Sheep
• Conjugate: Alexa Fluor 532

TREM2 Antibody [Alexa Fluor® 532] Summary

• Immunogen: Mouse myeloma cell line NS0-derived recombinant mouse TREM2b
  Leu19-Pro168
  Accession # Q99NH8
• Specificity: Detects mouse TREM2 in direct ELISAs and Western blots.
• Isotype: IgG
• Clonality: Polyclonal
• Host: Sheep
• Purity: Antigen Affinity-purified

Applications/Dilutions

• Dilutions:
  • ELISA
  • Immunocytochemistry
  • Knockout Validated
  • Western Blot

Packaging, Storage & Formulations

• Storage: Protect from light. Do not freeze. 12 months from date of receipt, 2 to 8 °C as supplied
• Buffer: Supplied 0.2mg/ml in 1X PBS with RDF1 and 0.09% Sodium Azide
• Purity: Antigen Affinity-purified

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for TREM2 Antibody [Alexa Fluor® 532]

• PLOSL2
• TREM2
• TREM-2
• Trem2a
• Trem2b
• Trem2c
• TREM-2triggering receptor expressed on myeloid cells 2a
• Triggering receptor expressed on monocytes 2
• triggering receptor expressed on myeloid cells 2

Background

TREM2 (Triggering Receptor Expressed by Myeloid cells) is an Ig superfamily cell surface receptor that activates a number of myeloid cell types (1). It is a member of a small gene family located on human chromosome 6p21 and mouse chromosome 17 in a region linked to the MHC (2). A single human TREM2 gene has been described, however, two closely related orthologs were reported in mouse (3). The proteins differ by only three amino acids and were designated TREM2a and TREM2b. TREM2 is type I transmembrane protein consisting of a single extracellular immunoglobulin (V-like) domain, a transmembrane domain with a positively charged lysine residue, and a short cytoplasmic tail (1). It associates with the signal adapter protein, DAP12, for signaling and function. DAP12 has a cytoplasmic ITAM that is phosphorylated upon ligand binding leading to the subsequent activation of cytoplasmic tyrosine kinases. TREM2 is expressed by immature monocyte-derived dendritic cells (DC), and expression is down-regulated upon activation of DC by microbial products and costimulatory signals (4). Ligation of TREM2 on immature DC with anti-TREM2 antibodies results in partial DC activation and the up-regulation of CCR7 and some co-stimulatory molecules. A role for TREM2 in the functioning of osteoclasts and microglia is suggested by the discovery that homozygous loss-of-function mutations in either TREM2 or DAP12 result in Nasu-Hakola disease characterized by a combination of presenile demetia and bone cysts (5). In vitro studies indicate that the differentiation of myeloid precursors into osteoclasts is dramatically impaired in TREM2 deficient individuals (6).

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.